Back
Acacia Research 10K Form
Sell
33
ACTG
Acacia Research
Last Price:
4.29
Seasonality Move:
2.12%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-10 | 10Q | ACTG/Acacia Research Quarterly |
2024-03-15 | 10K | ACTG/Acacia Research Annual |
2023-11-13 | 10Q | ACTG/Acacia Research Quarterly |
2023-08-03 | 10Q | ACTG/Acacia Research Quarterly |
2023-05-11 | 10Q | ACTG/Acacia Research Quarterly |
2023-03-17 | 10K | ACTG/Acacia Research Annual |
Receive ACTG News And Ratings
See the #1 stock for the next 7 days that we like better than ACTG
ACTG Financial Statistics
Sales & Book Value
Annual Sales: | $125.1M |
---|---|
Cash Flow: | $-135.76M |
Price / Cash Flow: | 0 |
Annual Sales: | $5.59 |
Price / Book: | 0.85 |
Profitability
EPS (TTM): | 0.63810 |
---|---|
Net Income (TTM): | $67.76M |
Gross Margin: | $72.27M |
Return on Equity: | 12.96% |
Return on Assets: | 10.99% |
Acacia Research Earnings Forecast
Key Acacia Research Financial Ratios
- The Gross Profit Margin over the past 27 years for ACTG is 57.77%.
- The Selling, General & Administrative Expenses for ACTG have been equal to 40.45% of Gross Profit Margin.
- The Research & Development expenses have been 0.59% of Revenue.
- The Interest Expense is 2.88% of Operating Income.
- The Net Earning history of ACTG is 53.60% of Total Revenues.
- Per Share Earnings over the last 29 years have been positive in 14 years.
Acacia Research Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Financial Services |
Sector: | Financials |
Current Symbol: | ACTG |
CUSIP: | 003881 |
Website: | acaciaresearch.com |
Debt
Debt-to-Equity Ratio: | 0.15 |
---|---|
Current Ratio: | 11.17 |
Quick Ratio: | 10.42 |
Price-to-Earnings
Trailing P/E Ratio: | 8.16 |
---|---|
Forward P/E Ratio: | 0 |
ACTG Technical Analysis vs Fundamental Analysis
Sell
33
Acacia Research (ACTG)
is a Sell
Is Acacia Research a Buy or a Sell?
-
Acacia Research stock is rated a Sell
The current Acacia Research [ACTG] share price is $4.32. The Score for ACTG is 33, which is 34% below its historic median score of 50, and infers higher risk than normal.